Biocon shares in focus as it gets additional global market entry for Yesintek to treat autoimmune diseases

Yesintek is a human interleukin-12 and -12 antagonist that disrupts IL-12 and IL-23 mediated signaling in immune mediated diseases and has been approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.